Olaparib for Metastatic Castration-Resistant Prostate Cancer

Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Kim N., Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Przemyslaw Twardowski, Niven Mehra, Carsten Goessl, Jinyu Kang, Joseph E. Burgents, Wenting Wu, Alexander Kohlmann, Carrie A. Adelman, Maha Hussain

New England Journal of Medicine, 2020

Université Paris-Sud, Hebron University, Royal Marsden Hospital, Vall d'Hebron Institute of Oncology, Institut Gustave Roussy, Centre Hospitalier de l’Université de Montréal, Carolina Urologic Research Center, Peter MacCallum Cancer Centre, BC Cancer Agency, Tulane University, University of Utah, Huntsman Cancer Institute, Spanish National Cancer Research Centre, Cancer Research Center, Centro de Investigación del Cáncer, Hospital Clínico Universitario Virgen de la Victoria, Centre Hospitalier Universitaire de Besançon, Saint John's Health Center, Radboud University Nijmegen, Radboud University Medical Center, AstraZeneca (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), AstraZeneca (United Kingdom), Robert H. Lurie Comprehensive Cancer Center of Northwestern University

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

2186

Citations

View on Google Scholar

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Abstract

Journal Details

Join JournalsHub

Welcome Back